Canaccord Genuity Group began coverage on shares of Nuformix (LON:NFX – Free Report) in a report issued on Tuesday morning,Digital Look reports. The brokerage issued a buy rating and a GBX 293 ($3.81) target price on the stock.
Nuformix Stock Performance
Shares of NFX opened at GBX 0.08 ($0.00) on Tuesday. Nuformix has a fifty-two week low of GBX 0.04 ($0.00) and a fifty-two week high of GBX 0.30 ($0.00). The business has a 50-day moving average of GBX 0.08 and a 200 day moving average of GBX 0.07. The firm has a market cap of £948,493.00, a P/E ratio of -2.34 and a beta of 1.22.
Nuformix (LON:NFX – Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- What Are Earnings Reports?
- 3 Must-Own Stocks to Build Wealth This Decade
- Ride Out The Recession With These Dividend Kings
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
